ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Acelyrin, Inc. (“Acelyrin” or “the Company”) (NASDAQ: SLRN) complied with federal securities laws. On September 11, 2023, Acelyrin announced top-line results from a clinical trial of izokibep, revealing that the drug failed to meet the primary endpoint of showing statistically significant reduction in abscesses and inflammatory nodules compared to patients receiving a placebo. The Company attributed the results to patient discontinuations and placebo responses. Following this news, the price of the Company’s stock dropped.
If you purchased Acelyrin stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/acelyrin/ to discuss your legal rights.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
